Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174260
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGriguolo, Gaia-
dc.contributor.authorBrasó Maristany, Fara-
dc.contributor.authorGonzalez Farré, Blanca-
dc.contributor.authorPascual, Tomás-
dc.contributor.authorChic, Núria-
dc.contributor.authorSaurí, Tamara-
dc.contributor.authorKates, Ronald-
dc.contributor.authorGluz, Oleg-
dc.contributor.authorMartínez, Débora-
dc.contributor.authorParé, Laia-
dc.contributor.authorTsvetkova, Vassilena-
dc.contributor.authorPesantez, David-
dc.contributor.authorVidal Losada, Maria Jesús-
dc.contributor.authorAdamo, Barbara-
dc.contributor.authorMuñoz Mateu, Montserrat-
dc.contributor.authorGalván, Patricia-
dc.contributor.authorBarberá, Laura-
dc.contributor.authorCuatrecasas Freixas, Miriam-
dc.contributor.authorChristgen, Mathias-
dc.contributor.authorKreipe, Hans-
dc.contributor.authorMonge Escartín, Inés-
dc.contributor.authorVillagrasa, Patricia-
dc.contributor.authorSoy Muner, Dolors-
dc.contributor.authorGiarratano, Tommaso-
dc.contributor.authorDieci, Maria Vittoria-
dc.contributor.authorConte, Pierfranco-
dc.contributor.authorHarbeck, Nadia-
dc.contributor.authorGuarneri, Valentina-
dc.contributor.authorPrat Aparicio, Aleix-
dc.date.accessioned2021-02-24T16:59:37Z-
dc.date.available2021-02-24T16:59:37Z-
dc.date.issued2020-07-14-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/2445/174260-
dc.description.abstractTrastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,-
dc.format.extent15 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers12071902-
dc.relation.ispartofCancers, 2020, vol. 12(7), num. 1902-
dc.relation.urihttps://doi.org/10.3390/cancers12071902-
dc.rightscc-by (c) Griguolo, Gaia et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCàncer de mama-
dc.subject.classificationReceptors d'hormones-
dc.subject.otherBreast cancer-
dc.subject.otherHormone receptors-
dc.titleERBB2mRNA expression and response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-positive breast cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec704764-
dc.date.updated2021-02-24T16:59:37Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
704764.pdf3.27 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons